Actinium Pharmaceuticals (ATNM) Stock Statistics & Valuation Metrics

Actinium Pharmaceuticals has a market cap or net worth of $49.60M. The enterprise value is -$32.02M.

Actinium Pharmaceuticals has 31,195,890 shares outstanding. The number of shares has decreased by -2.65% in one year.

Actinium Pharmaceuticals’s return on equity (ROE) is -1.17 and return on invested capital (ROIC) is -60.75%.

The current PE Ratio of Actinium Pharmaceuticals is ―. Actinium Pharmaceuticals’s PEG ratio is 0.03.

In the last 12 months, Actinium Pharmaceuticals had revenue of 0.00 and earned -38.24M in profits. Earnings per share was -1.27.

In the last 12 months, operating cash flow was -25.04M and capital expenditures 0.00, giving a free cash flow of -25.04M billion.

Actinium Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Actinium Pharmaceuticals upcoming earnings date is Mar 13, 2026, TBA (Confirmed).

Actinium Pharmaceuticals as a current ratio of 9.14, with Debt / Equity ratio of 8.29%

In the past 12 months, Actinium Pharmaceuticals has paid 0.00 in taxes.

Actinium Pharmaceuticals EV to EBITDA ratio is 0.89, with an EV/FCF ratio of 1.01.

Actinium Pharmaceuticals has $53.39M in cash and marketable securities with $1.14M in debt, giving a net cash position of $52.25M billion.

Gross margin is -0.44%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Actinium Pharmaceuticals is $6.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy